<?xml version="1.0" encoding="UTF-8"?>
<p>Middle East respiratory syndrome caused by MERS-CoV may have been transmitted to humans through infected camels. The MERS outbreak between September 2012 and January 2020 was reported to have caused 2519 laboratory-confirmed cases and 858 associated deaths globally, giving a case-fatality rate of 34.4%.
 <xref rid="b13-dic-2020-4-15" ref-type="bibr">13</xref> As of 2019, there is still no effective vaccine or treatment for this disease, although a number of antiviral medications have been investigated.
 <xref rid="b14-dic-2020-4-15" ref-type="bibr">14</xref> A 2019 systematic review of therapeutic agents against MERS-CoV showed that there is still no general consensus on the optimal treatment strategy for MERS-CoV infection.
 <xref rid="b15-dic-2020-4-15" ref-type="bibr">15</xref> The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) was the first randomised controlled trial to assess the feasibility, efficacy, and safety of a combination of lopinavir/ritonavir and interferon-β1b in hospitalised patients with MERS.
 <xref rid="b16-dic-2020-4-15" ref-type="bibr">16</xref>,
 <xref rid="b17-dic-2020-4-15" ref-type="bibr">17</xref> The trial was started in July 2016 and enrolled 194 participants, although results have yet to be published.
 <xref rid="b16-dic-2020-4-15" ref-type="bibr">16</xref>,
 <xref rid="b17-dic-2020-4-15" ref-type="bibr">17</xref> At present, only three potential MERS-CoV vaccine candidates have progressed to phase I clinical trials. It is very likely that no MERS vaccine will be available in the near future.
 <xref rid="b18-dic-2020-4-15" ref-type="bibr">18</xref>
</p>
